FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug
Briefly mentioned in Vertex Pharmaceuticals’ JPM presentation Monday, the FDA has put an IND for Vertex’s new Type 1 diabetes cell therapy, VX-264, on hold. CEO Reshma Kewalramani noted the company has yet to receive the FDA’s questions on the experimental treatment.
VX-264 uses the same islet cells as Vertex’s T1D cell therapy VX-880, which is already in the clinic. In June, Vertex presented data on two patients in the VX-880 trial — the first patient became insulin-independent at around 9 months after treatment, while the second saw a 30% reduction in insulin use at around 5 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
